Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Age... (tic functions required for the prolifera...)

Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102

Date:2/26/2013

tic functions required for the proliferation of cancer cells, and tipiracil hydrochloride (TPI), an inhibitor of thymidine phosphorylase (which degrades FTD) that maintains an effective blood concentration of FTD. TAS-102 is administered twice daily to achieve a total daily dose of 70mg/square meter for five days followed by two days of rest and then repeated a second time. This is followed by a 14-day rest period to make a 28-day schedule for one course.

About TAS-102 Phase II Clinical Trial
The Phase II clinical trial was conducted with the participation of 172 patients at 20 medical institutions in Japan from August 2009 to April 2010. The target for the study is an area for which there is currently no fully established therapy in Japan -- specifically, patients refractory to standard chemotherapy for metastatic colorectal cancer who have received at least two or more regimens containing fluoropyrimidine, irinotecan, and oxaliplatin. Patients were randomly assigned TAS-102 (114 cases) or a placebo (58 cases). The primary endpoint was overall survival.

About Global Phase III Clinical Trial (RECOURSE)
The Global Phase III Clinical Trial (RECOURSE) is a randomized, double-blind comparative study of TAS-102 versus a placebo. It is a global Phase III clinical trial that is scheduled to enroll a total of 800 patients from Japan, North America, Europe, and Australia. Patient enrollment began in June 2012. The subjects are patients with unresectable, advanced, recurrent colorectal cancer that is refractory to standard chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab, and EGFR monoclonal antibody in cases of KRAS wild-type tumor). The trial will compare patients randomly assigned to receive TAS-102 or placebo in order to investigate the efficacy and safety of TAS-102. The p
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
2. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
3. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
5. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
6. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
7. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
8. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
9. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
10. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
11. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4

Post Your Comments:

(Date:5/17/2013)... Research explores data on ... also to be presented ... the global specialty biopharmaceutical company, announces that it will ... American Psychiatric Association (APA) 166th Annual Meeting in ... being presented represent Shire,s ongoing commitment to the clinical ...

(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The ... recombinant proteins, is placing renewed emphasis on alternate ... rise as a number of factors are converging ... pharmaceutical makers and their delivery device partners . ... refractory conditions, the growing trend toward self-administration for ...

(Date:5/17/2013)... , May 17, 2013 Boehringer Ingelheim ... respiratory disease at the American Thoracic Society International ... , May 17 – 22. ... approved for the treatment of chronic obstructive pulmonary ... as well as investigational compounds for asthma, idiopathic ...

[0] Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting [0] Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment [0] Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference

... As part of a three-year global initiative to identify ... problems around the world, Boehringer Ingelheim and Ashoka,s Changemakers® ... Health: Achieving Individual, Family, and Community Well-Being ... the most innovative models and solutions that are transforming ...

... Ascension Orthopedics, Inc., a world leader in PyroCarbon orthopedic ... Glenoid. The Mini Glenoid is yet another addition to the ... way to address glenoid arthritis. "The Mini ... the glenoid as well as load-share with the peripheral glenoid ...

Cached Medicine Technology:Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition 2 Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition 3 Ascension Orthopedics Announces Market Release of TITAN™ Inset Mini Glenoid 2

Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition Ascension Orthopedics Announces Market Release of TITAN™ Inset Mini Glenoid

(Date:5/19/2013)... 2013 The legal team at Pulaski ... a concerted effort to connect women and families coping ... drugs Yaz, Yasmin & Ocella with the legal representation ... on the notorious birth control drugs as well as ... , Yaz, Yasmin & Ocella were very popular birth ...

(Date:5/18/2013)... (PRWEB) May 18, 2013 Daily Gossip issued ... a new review on their page. John Colston, Daily Gossip’s ... to Shaun Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan ... sustain that carbs are healthy at a time when nutritionists ... from highly caloric products. , The diet is based ...

(Date:5/18/2013)... Also known as bariatric surgery , ... surgery that guarantees patients long-term weight loss. Dr. Naim ... give readers a brief tutorial on this revolutionary weight ... New York City’s Mount Sinai School of Medicine. After ... fellowship in Minimally Invasive Bariatric Surgery. He has also ...

(Date:5/18/2013)... Children who swallow high-powered magnets often need surgery and ... a new study. The researchers, from the Louisiana ... more than 79 percent of children who swallowed very ... procedure, in which a tube containing a camera is ... these cases can be treated through observation or by ...

(Date:5/18/2013)... There are significant cost and risk factors ... or treat gastrointestinal problems, according to research presented ... study by New York Presbyterian Hospital and Weill-Cornell ... substantially reduce the cost and risk of managing ... to affect nearly 25 percent of adults, researchers ...

Breaking Medicine News(10 mins):Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2 Health News:Everything You Need to Know About Lap Band Surgery 2 Health News:Everything You Need to Know About Lap Band Surgery 3 Health News:Swallowing Magnets Can Be Fatal for Children 2 Health News:New research identifies practice changes to improve value and quality of GI procedures 2

[0] Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers [0] 14 Day Rapid Fat Loss Plan Review of Shaun Hadsall's Diet and Workout Secrets Revealed By Daily Gossip [0] Everything You Need to Know About Lap Band Surgery [0] Swallowing Magnets Can Be Fatal for Children [0] New research identifies practice changes to improve value and quality of GI procedures

... , TUESDAY, Aug. 16 (HealthDay News) -- For some ... of the disease who find standard treatments either intolerable ... relief. A new injectable treatment called pegloticase (brand ... patients, but researchers say that for the roughly ...

... Pneumonia kills more children around the world than any ... the causes of childhood pneumonia across many countries was ... study called the Pneumonia Etiology Research for Child Health ... 5 African and 2 Asian research sites coordinated by ...

... was a dramatic increase in the number of children,s flu-related hospital ... agency says. Over that time, flu rose from 65th to ... younger go to the hospital, according to a report from the ... found that skin infections rose from 13th to 7th in the ...

... Foundation launched a major new collaboration created with ... with its announcement that it will provide funding ... interventional radiology during 2012󈝹 in the Howard Hughes ... "The SIR Foundation, which seeks to further ...

... new study has shown the Flexible-Fiber CO2 laser to ... (TSC) without the,line of sight problems encountered with conventional ... Medical Center (BMC) and Boston University School of Medicine ... Neurosurgery . This is the first study to report ...

... for 15 minutes a day, or 92 minutes per week, ... who are inactive, according to a study published today in ... reduced deaths from any cause by 14 percent," said study ... The University of Texas MD Anderson Cancer Center Department of ...

Cached Medicine News:Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 2 Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 3 Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 4 Health News:Largest global childhood pneumonia etiology study launched 2 Health News:Largest global childhood pneumonia etiology study launched 3 Health News:Society of Interventional Radiology Foundation funds Howard Hughes Medical Institute Award 2 Health News:Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery 2 Health News:Study finds 15 minutes of moderate daily exercise lengthens life 2 Health News:Study finds 15 minutes of moderate daily exercise lengthens life 3

New Drug May Relieve Severe, Tough-to-Treat Gout Largest global childhood pneumonia etiology study launched More Kids Hospitalized for Flu, Skin Infections Society of Interventional Radiology Foundation funds Howard Hughes Medical Institute Award Study finds flexible-fiber CO2 laser safe in endoscopic endonasal transsphenoidal surgery Study finds 15 minutes of moderate daily exercise lengthens life

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

Medicine Products:

Cr, Blood Coxiella burnetii IgM Antibody, IFA Coxsackie A9 Virus Antibodies by CF Coxiellaburnetii (Q-Fever) Antibody IgG, Phase II by IFA